138 related articles for article (PubMed ID: 38135372)
1. Oral decitabine plus cedazuridine versus intravenous decitabine.
de Witte T
Lancet Haematol; 2024 Jan; 11(1):e2-e3. PubMed ID: 38135372
[No Abstract] [Full Text] [Related]
2. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy].
Tauveron-Jalenques U; Lambert J
Bull Cancer; 2024 May; 111(5):435-436. PubMed ID: 38582741
[No Abstract] [Full Text] [Related]
3. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.
Candoni A
Lancet Haematol; 2024 Apr; 11(4):e245-e246. PubMed ID: 38452789
[No Abstract] [Full Text] [Related]
4. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
6. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Feld J; Tremblay D; Navada SC; Silverman LR
Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
[TBL] [Abstract][Full Text] [Related]
7. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract][Full Text] [Related]
8. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
[No Abstract] [Full Text] [Related]
9. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
10. Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Montesinos P; Sossa-Melo C
Lancet Haematol; 2023 Nov; 10(11):e866-e867. PubMed ID: 37914474
[No Abstract] [Full Text] [Related]
11. Activity of decitabine combined with all-
Rummelt C; Grishina O; Schmoor C; Crysandt M; Heuser M; Götze KS; Schlenk RF; Döhner K; Salih HR; Heil G; Müller-Tidow C; Brugger W; Kündgen A; De Wit M; Giagounidis A; Scholl S; Neubauer A; Krauter J; Bug G; Al-Ali HK; Wäsch R; Becker H; May AM; Duyster J; Hackanson B; Ganser A; Döhner H; Lübbert M
Haematologica; 2023 Aug; 108(8):2244-2248. PubMed ID: 36601981
[No Abstract] [Full Text] [Related]
12. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
[No Abstract] [Full Text] [Related]
13. Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Aribi A; Salhotra A; Ball B; Stein A; Marcucci G; Pullarkat V
Leuk Lymphoma; 2023 Apr; 64(4):897-899. PubMed ID: 36850055
[No Abstract] [Full Text] [Related]
14. Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Ramsey HE; Oganesian A; Gorska AE; Fuller L; Arrate M; Boyd K; Keer H; Azab M; Savona MR
Target Oncol; 2020 Apr; 15(2):231-240. PubMed ID: 32222953
[TBL] [Abstract][Full Text] [Related]
15. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G; Griffiths EA; Steensma DP; Roboz GJ; Wells R; McCloskey J; Odenike O; DeZern AE; Yee K; Busque L; O'Connell C; Michaelis LC; Brandwein J; Kantarjian H; Oganesian A; Azab M; Savona MR
Blood; 2020 Aug; 136(6):674-683. PubMed ID: 32285126
[TBL] [Abstract][Full Text] [Related]
16. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Patel AA; Cahill K; Saygin C; Odenike O
Blood Adv; 2021 Apr; 5(8):2264-2271. PubMed ID: 33904891
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
18. Decitabine/Cedazuridine: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(13):1373-1378. PubMed ID: 32860582
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Santini V; Ossenkoppele GJ
Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
[TBL] [Abstract][Full Text] [Related]
20. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
